The latest headlines across every section, pulled from official and open-access sources.
Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.
Private equity giant KKR is expanding its healthcare portfolio with a deal to take medtech manufacturing giant Integer private for approximately $5.7 billion.
Latigo Biotherapeutics has fleshed out its plans for an IPO to finance the development of its clinical-stage pipeline of non-opioid pain management drugs.
A phase 2 trial of Merck & Co.’s anti-TL1A monoclonal antibody has missed its primary endpoint, closing off one avenue for expansion of an asset acquired in a $10.8 billion takeover. The setback was offset by a midphase win in another indication.
Pathos AI has agreed to pay $125 million for a bispecific antibody-drug conjugate from China’s Alphamab Oncology, while adding a Big Pharma partner in the form of AstraZeneca.
CDC recommends avoiding nonessential travel to Haut-Uélé and Tshopo provinces in the Democratic Republic of the Congo (DRC) due to the current Bundibugyo virus disease (BVD) outbreak.
CDC recommends practicing enhanced precautions for travel to Uganda or to provinces in the Democratic Republic of the Congo (DRC) not affected by the current Bundibugyo virus disease (BVD) outbreak. Country List : Democratic Republic of the Congo, Uganda Country List : Democratic Republic of the Congo, Uganda Country List : Democratic Republic of the Congo, Uganda
J. S. Yoder et al.
BD is recalling certain BD Intraosseous Vascular Access System Needle Sets due to difficulty removing the obturator (stylet) following placement.
CDC recommends avoiding all travel to Ituri and Nord-Kivu (North-Kivu) provinces in the Democratic Republic of the Congo (DRC) due to the current Bundibugyo virus disease (BVD) outbreak unless traveling for humanitarian aid or emergency response.
Obstetrics and Gynecology
Health Policy
Pediatrics
Ethics
This cohort study analyzes factors associated with abandonment of newly prescribed buprenorphine among US adults from 2020 to 2024.
This cohort study examines whether childhood body mass index (BMI) is associated with reproductive outcomes later in life among women in Denmark.
This cohort study evaluates patient characteristics associated with completion of screening for health-related social needs, identification of at least 1 need, total identified needs, and assistance requests across a multistate US health system.
This cohort study describes the incidence of Kawasaki disease overall across 50 years and by age groups to assess whether epidemiologic patterns changed after the COVID-19 pandemic.
This qualitative study explores social acceptance of artificial intelligence in health care.
This cohort study describes 6-month chronic pain trajectories using weekly assessments and evaluates the value of routinely collected baseline sociodemographic and clinical variables in estimating trajectories.
This cohort study evaluates racial and ethnic differences in the diagnostic performance of transvaginal ultrasound for detecting endometrial neoplasia.
This economic evaluation assesses the cost-effectiveness and life-years gained of endovascular vs bypass revascularization for chronic limb-threatening ischemia.
HHS is reviving a rebate program for 340B drug discounts after the previous pilot was blocked in court earlier this year. Providers say the change will burden already cash-strapped providers with new administrative and financial costs. The post HHS Is Reviving Its 340B Rebate Push — And Providers Are None Too Pleased appeared first on MedCity News .
The Center for Drug Evaluation and Research (CDER) takes an active role in helping prepare the nation to respond to terrorist events, emerging health threats, and emergency response to natural and man-made crises.